Market Size (2015)
2015
$2.91B
Vertical: HealthcareBase Year: 201713 Sections
Market Size (2015)
2015
$2.91B
Projected (2023)
2023
$3.98B
CAGR (2015–2023)
4.0%
4.0%Key Players
110+
Active pharmaceutical ingredients are used in the manufacturing of pharmaceutical formulations. Duloxetine is a serotonin-norepinephrine reuptake inhibitor used in the treatment of depression and anxiety. Additionally, it is used to help relieve neuropathic pain in people with diabetes or ongoing pain due to medical conditions such as arthritis, chronic back pain, or fibromyalgia. Several factors such as increasing cases of anxiety, the growing prevalence of depression, increasing penetration of generic drugs, the growing trend of outsourcing, strong drug pipeline, and growing demand for newly developed small molecule drugs are anticipated to boost the market growth over the assessment period.
The global duloxetine API was valued at USD 3,213.9 million in 2017, and the market is estimated to grow at USD 3,985.0 million by 2023. In 2017, the Americas accounted for the largest market share of 34.8% with a market value of USD 1,119.1 million, followed by Europe with a market value of USD 975.2 million in 2017.
The global duloxetine API has been segmented based on application and region.
Based on application, the major depressive disorder segment accounted for the largest market share of 33.36% in 2017, with a market value of USD 1,072.1 million, which is projected to register a CAGR of 3.13% during the forecast period.
The Duloxetine API Market market is projected to grow at a CAGR of 4.0% from 2015 to 2023.
Historical performance and future projections (2020–2030, USD Billion)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Size (USD Mn)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansDuloxetine is a serotonin-norepinephrine reuptake inhibitor used to treat depression, anxiety, and pain. The growing rates of anxiety, the increasing prevalence of depression, rising penetration of generic drugs, and the growing trend of outsourcing are expected to support the market growth over the forecast period. However, changing economic conditions globally and side-effects of duloxetine are likely to hamper the growth of the global duloxetine API market.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2017
Historical Period
2015 – 2017
Forecast Period
2017 – 2023
Primary Interviews
150+
Historical data (2015–2017) and forecast period (2017–2023)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThreat of New Entrants
The threat of new entrants is high in the global duloxetine API market. In Porter’s Five Forces Analysis, the ‘Threat of New Entrants’ refers to the threat that new competitors pose to existing competitors in an industry. A profitable industry will attract more competitors looking to achieve profits. As the number of entrants increases, the profitability of the present players in the industry subsequently decreases. The global duloxetine API market has a high threat of new entrants, threatening the existing players. Moreover, the cost involved in R&D is comparatively high which does not comfort the new entrants to enter the market easily.
Bargaining Power of Suppliers
Bargaining power of suppliers in the global duloxetine API market is medium. The bargaining power of suppliers estimates how easy it is for the suppliers to influence the prices of the final products made by innovators. Businesses must obtain the necessary resources that they need from the resource suppliers to carry out their activities.
In the global duloxetine API industry, the number of suppliers is comparatively less than the number of firms operating in the sector, and only a few of them have a large hold on the duloxetine API market. The recessionary pressures have reduced the price of many components and raw materials due to downward demand trends. Moreover, the switching cost of these suppliers is also medium as the suppliers tend to enter long-term associations with the manufacturers.
Threat of Substitutes
The threat of substitutes in the global duloxetine API market is medium to low. The substitute to the duloxetine API can only be in the form of large molecules. Buyer propensity to substitute is moderate due to the lesser availability of substitutes in this market. In addition, the high degree of switching cost minimizes the threat of substitutes.
Bargaining Power of Buyers
The bargaining power of the buyer is considered to have a low impact on the industry. The bargaining power of the buyers evaluates how easy it is for the buyers to affect the price of pharmaceutical products. There is a low number of players with capabilities to manufacture high-end drugs.
Also, the high differential advantage of the duloxetine API market coupled with low or poor existing substitutes for high tech products makes the position of the manufacturers strong. However, the latest trend of mergers between large healthcare providers coupled with strategies such as demand pooling by multiple players is increasing the power of the buyers.
Intensity of Rivalry
The degree of competition in the global duloxetine API market is high. The moderate degree of product differentiation among existing players increases the intensity of rivalry in the market. The intensity of competitive rivalry evaluates the capability and the level of rivalry among competitors in the market. It also refers to the extent to which firms within an industry put pressure on one another and limit each other’s profit potential. Rivalry among industry players can affect industry profits through downward pressure on prices, increased innovation, increased advertising, and increased service/product improvements, among others.
Market estimates by geography (2023)
InsightAmericas leads with $1.40B by 2023.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2015 | 2017 | 2023 | CAGR | SHARE |
|---|---|---|---|---|---|
| Middle East and Africa | $199.60M | $239.40M | $257.10M | 3.2% | 6% |
| Americas | $1.00B | $1.22B | $1.40B | 4.3% | 35% |
| Asia Pacific | $827.10M | $964.40M | $1.15B | 4.2% | 29% |
| Europe | $878.00M | $1.06B | $1.17B | 3.7% | 29% |
| Total | $2.91B | $3.49B | $3.98B | 4.0% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.

Analytical insights on Duloxetine API Market covering market dynamics, competitive landscape, and strategic outlook.
The Duloxetine API Market market is projected to reach $3.98B by 2023, growing at 4.0% CAGR.
The duloxetine drug primarily targets major depressive disorder (MDD), generalized anxiety disorder (GAD), and pain related to diabetic peripheral neuropathy, among others. Factors such as the rising rates of anxiety cases, increasing prevalence rates of depression, increasing penetration of generic versions of drugs, strong drug pipeline, growing demand for newly developed small molecule drugs, and the growing trend of outsourcing are major drivers propelling market growth.
The people suffering from anxiety are increasing at a fast pace. According to a report by the World Health Organization (WHO), the portion of the global population with anxiety disorders was estimated to be 3.6% in 2015. It also stated that in 2015 the total estimated number of people living with anxiety disorders globally was about 264 million. According to the same source, in 2015, about 36.17 million cases of anxiety disorders were reported in the European region. Moreover, according to the updated report by the Anxiety and Depression Association of America, in 2017, approximately 30% of the adult population in North America had anxiety disorders. Therefore, as duloxetine is used to treat anxiety cases, the increasing prevalence of anxiety is expected to provide favorable background for the market to grow over the forecast period.
Over the past years, the pharmaceutical industry has been focusing more on the development of biologics. As a result, the API market has suffered tremendous regression. Many custom manufacturing organizations (CMOs) have shifted their focus to high-value biologics manufacturing.
Nevertheless, the attention of the pharmaceutical industry seems to be back with small molecule therapeutics. Many companies have come up with generic versions of duloxetine. For instance, in June 2014, Dr. Reddy's Laboratories launched duloxetine delayed-release capsule United States Pharmacopeia (USP) 20 mg, 30 mg, and 60 mg in the US market. Thus, the growing worldwide demand for effective drugs and the upcoming launch of several blockbuster drugs would create more opportunities in the near future.
Austerity measures in Europe are putting pressures on margins for drug manufacturers. For instance, in the past, Germany has implemented a free price-setting mechanism which had led pharma companies to enjoy high prices of patented pharmaceutical products. But since the economic downfall in the region, Germany started seeking chances to curb its expenses and to control the increasing pharmaceutical spending. The country passed the act for restructuring the pharmaceutical market in statutory health insurance which came into effect in 2011. According to the regulation, pharmaceutical manufacturers must demonstrate the additional therapeutic benefit of newly approved pharmaceuticals compared to their competitors.
Furthermore, German drug prices are frequently used as a reference point by healthcare providers in other European countries. This has put severe pricing pressures on drug manufacturers which led many to look for alternative ways to decrease their cost of manufacturing to survive in the harsh market. The economic condition in Europe is a major factor of worry for the growth of the global duloxetine API market.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 110 companies operating in the Duloxetine API Market market, including revenue, employee count, and market positioning where available.
Showing 110 of 110 companies
Shionogi Inc.
Company Headquarters: Osaka, Japan Founded: 1878 Company Working: Shionogi Inc. is a development organization capable of conducting multiple simultaneous late-stage clinical programs and submitting new drug application (NDA) filings worldwide. The company has established commercial capabilities to market their products globally effectively.
Apotex Inc.
Company Headquarters: Canada Founded: 1974 Workforce: 10,000+ Company Working: Apotex Inc. (Apotex) is the largest Canadian-owned pharmaceutical company. It is also the largest producer of generic medicines in the country. Apotex is a global, fully integrated API R&D company. It has many facilities across the globe located in Canada, India, Mexico, and China. The Apotex Group of Companies is comprised of Apotex Generics, Apotex Active Pharmaceutical Ingredients, Apobiologix, and ApoPharma (Innovative Products) through vertical integration. The company exports to more than 115 countries and operates in more than 45 countries. Globally, it produces approximately 25 billion doses per year, which are used to fill over 89 million prescriptions in Canada alone. Apotex is into unit dose products, injectable products, and specialty products.
Hetero
Company Headquarters: Hyderabad, India Founded: 1997 Workforce: 10 Company Working: Hetero is a research-based global pharmaceutical company focused on the development, manufacturing, and marketing of active pharmaceutical ingredients (API), intermediate chemicals, and finished dosages. The company is vertically integrated for research discovery, process chemistry, API manufacturing, formulation development, and commercialization. It is an international supplier of over 200 products from a wide range of therapeutic categories. Majority of them are approved by various regulatory authorities of the USFDA, WHO-Geneva, Australian TGA, Spanish agency of medicines & health care products, ANVISA-Brazil, IDA-Netherlands, etc. It markets its products in over 138 countries across the globe.
Shodhana Laboratories Ltd
Company Headquarters: Hyderabad, India Founded: 2000 Workforce: ~700 Company Working: Shodhana Laboratories Ltd (Shodhana) is an active pharmaceutical ingredients and intermediates manufacturing company. The company caters to both domestic and global markets. Shodhana is engaged in manufacturing and marketing bulk actives, pharma chemicals, and ingredients for pharmaceutical applications. It manufactures a wide range of products in the areas of antidepressant, anti-emetic, anti-anginal, anti-Parkinson, anti-diarrheal, anti-hypertensive, and beta-adrenergic, amongst others. Some of the products manufactured by Shodhana include Carvedilol, Mizolastine, Carbidopa, Racecadotril, Rivastigmine, Ondansetron, Ranolazine, Escitalopram Oxalate, Citalopram Hydrobromide, Escitalopram Oxalate, Dapoxetine Hydrochloride, and others. It exports its products to over 50 countries.
Zydus Cadila
Company Headquarters: Ahmedabad, India Founded: 1952 Workforce: 23,000+ Company Working: Zydus Cadila is one of the leading Indian pharmaceutical companies. It has in-depth domain expertise in the field of healthcare. It also has strong capabilities across the range of the pharmaceutical value chain. The company provides comprehensive and complete healthcare solutions ranging from formulations to APIs and animal healthcare products to wellness products. Its presence spreads across four continents. The company ranks fourth in the Indian pharmaceutical industry with manufacturing and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh, and Sikkim. Globally, Zydus Cadila has a strong presence in regulated markets of the US, Europe (France and Spain), and the high-profile markets of Latin America and South Africa. It also has a strong presence in 25 other emerging markets worldwide.
Eli Lilly and Company
Company Headquarter: Indianapolis, Indiana, US Founded: 1876 Workforce: 42,066 Company Working: Eli Lilly and Company is an American global pharmaceutical company. The company also has offices in Puerto Rico and 17 other countries. Its products are sold in approximately 125 countries. The company is listed on the New York Stock Exchange, and its shares had been a component of the S&P 500 Index since 1971. Lilly was the first company to mass-produce penicillin, the Salk polio vaccine, and insulin. Its achievements include being one of the first pharmaceutical companies to produce human insulin using recombinant DNA including Humulin, Humalog, and the first approved biosimilar insulin product in the US, Basaglar. Lilly is also the world's largest manufacturer and distributor of psychiatric medications including Prozac (Fluoxetine), Dolophine (Methadone), Cymbalta (Duloxetine), and Zyprexa (olanzapine). Some of the top competitors of Eli Lilly and Company are Pfizer Inc., GlaxoSmithKline PLC, Biogen, Sanofi, and Johnson and Johnson.
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Duloxetine API Market